Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Amortization of Deferred Charges (2022 - 2023)

Historic Amortization of Deferred Charges for Whitehawk Therapeutics (WHWK) over the last 2 years, with Q4 2023 value amounting to -$486000.0.

  • Whitehawk Therapeutics' Amortization of Deferred Charges rose 5440.9% to -$486000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was -$2.3 million, marking a year-over-year change of. This contributed to the annual value of -$3.1 million for FY2023, which is 15810.7% down from last year.
  • Whitehawk Therapeutics' Amortization of Deferred Charges amounted to -$486000.0 in Q4 2023, which was up 5440.9% from -$588000.0 recorded in Q3 2023.
  • In the past 5 years, Whitehawk Therapeutics' Amortization of Deferred Charges ranged from a high of -$149000.0 in Q3 2022 and a low of -$1.1 million during Q4 2022